#United States #San Diego #Caris Life Sciences #Precision Medicine #AACR Meeting

Caris Life Sciences to Present Significant Oncology Research at the AACR Annual Meeting 2026

Caris Life Sciences®, listed on NASDAQ under the symbol CAI, has made a notable announcement regarding its participation in the upcoming AACR Annual Meeting scheduled for April 17-22, 2026, in San Diego, California. This event will serve as a platform for Caris to present six innovative studies, emphasizing the integration of cutting-edge multimodal data to enhance cancer treatments.

The studies being featured are a collaboration between the Caris Precision Oncology Alliance® (Caris POA®) and several leading cancer centers. Centered around diverse cancer types such as breast, prostate, lung, and colorectal cancers, these studies aim to uncover remarkable insights that not only contribute to scientific knowledge but also have the potential to significantly improve patient outcomes.

Dr. James Hamrick, MD, MPH, Chairman of the Caris POA, stated, "These studies demonstrate the transformative potential of multimodal molecular data to uncover clinically meaningful patterns that would otherwise remain hidden. By combining deep genomic profiling with real world clinical evidence, Caris and its collaborators are generating insights that can directly inform treatment decisions and accelerate the development of more effective therapies for patients."

Research Highlights

The following posters will be presented during the conference, showcasing the impactful research:

1. Spatially resolved tumor-cell MHC class II shapes adaptive immunity and therapeutic response in triple-negative breast cancer.
- Session: Spatial Proteomics and Transcriptomics 1
- Date: Sunday, April 19, 2026
- Time: 2:00 PM – 5:00 PM PST
- Poster #: 1200/1
- Location: Poster section 47

2. Prognostic and predictive effects of TP53 co-mutations and RET fusion partners in RET-rearranged advanced NSCLC.
- Session: Biomarkers Predictive of Therapeutic Benefit 3
- Date: Monday, April 20, 2026
- Time: 9:00 AM – 12:00 PM PST
- Poster #: 2434/4
- Location: Poster section 40

3. AR copy number amplification and AR/KLK3 expression patterns reveal mechanisms of AR signaling inhibitor resistance in metastatic castration-resistant prostate cancer.
- Session: Molecular Targeted Therapy
- Date: Monday, April 20, 2026
- Time: 2:00 PM – 5:00 PM PST
- Poster #: 3910/16
- Location: Poster section 47

4. cBioPortal for cancer genomics.
- Session: AACR Project GENIE Genomic Characterization
- Date: Tuesday, April 21, 2026
- Time: 9:00 AM – 12:00 PM PST
- Poster #: 4097/2
- Location: Poster section 1

5. Distinct KRAS mutation codons and their relationship with microsatellite instability in colorectal carcinoma.
- Session: Precision Oncology and Real World Data
- Date: Tuesday, April 21, 2026
- Time: 9:00 AM – 12:00 PM PST
- Poster #: 5336/4
- Location: Poster section 46

6. MCM2 and the origin licensing complex as a potential node of ER+/HER2- breast cancer therapy resistance.
- Session: Real World Data to Provide Real World Evidence
- Date: Tuesday, April 21, 2026
- Time: 2:00 PM – 5:00 PM PST
- Poster #: 6647/16
- Location: Poster section 47

Caris Life Sciences' Vision

With a commitment to transforming healthcare, Caris develops innovative solutions through comprehensive molecular profiling techniques. Their advanced AI and machine learning capabilities facilitate the development of a large-scale multimodal clinico-genomic database, enabling them to unravel the molecular complexities of disease. Founded on the vision of harnessing precision medicine for improved human health, Caris maintains headquarters in Irving, Texas, along with branches across Phoenix, New York, Cambridge (MA), Tokyo, Japan, and Basel, Switzerland.

Through this groundbreaking research and collaboration at events like the AACR Annual Meeting, Caris Life Sciences strives to pave the way in precision oncology, ultimately aiming to enhance treatment options and therapeutic outcomes for patients globally.